ClinicalTrials.gg
CompletedNCT03397134Updated Apr 28, 2023Results posted

Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia

A Phase 3 interventional study of Placebo Oral Tablet and Roluperidone 32 mg in Negative Symptoms of Schizophrenia, sponsored by Minerva Neurosciences. Completed at 39 sites in 4 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-04-28.

Sponsored by Minerva Neurosciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
515
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 93 studies in Schizophrenia with a site in Ukraine — 1 open to participants now, 1 under way, 1 of them phase 3. Schizophrenia · Ukraine.

Enrollment
35th of 92
515 · median 446
Started
2017
with 8 others
Phase 3
68 of 93
1 open now
Registered
73rd of 93
by date

Among the 93 studies in Schizophrenia with a site in Ukraine, this one is the 35th largest by enrollment of the 92 interventional ones that give a count, is one of 9 that started in 2017, is one of 68 in phase 3, and was the 73rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 93 studies in Schizophrenia with a site in Ukraine is open now. Recruiting first, the newest first:

A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Schizophrenia with a site in Ukraine, or all of them as a file.
02

Study summary

MIN-101C07 is a multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of roluperidone in adult schizophrenia patients.The primary objective is to evaluate the efficacy of 2 fixed doses of roluperidone compared to placebo in improving the negative symptoms of schizophrenia over 12 weeks of double-blind treatment as measured by the change in Positive and Negative Syndrome Scale (PANSS) Marder negative symptoms factor score (NSFS) over 12 weeks.

03

Conditions studied

  • Negative Symptoms of Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient and patient's legal representative, if applicable, provided prior to the initiation of any study related procedures, and the patient is judged by the investigator as being capable of understanding the study requirements.
  • Male or female patient, 18 to 55 years of age, inclusive, and (BMI) \< 35 kg/m(2) at Screening.
  • Patient meets the diagnostic criteria for schizophrenia as defined in the (DSM-5), as established by a full psychiatric interview in conjunction with the Mini International Neuropsychiatric Interview.
  • Has a reliable caregiver or family member or health care personnel who can provide information towards assessment and support the patient in terms of compliance with the protocol. The caregiver must have contacts with the patient daily for at least 1 hour each time and is not expected to change during the trial.
  • Documented diagnosis of schizophrenia for at least 1 year before screening into the trial.
  • Patient is stable in terms of positive and negative symptoms of schizophrenia over the last 6 months according to his or her treating psychiatrist and based on documentation in the clinical chart.
  • Patient is currently an outpatient and has not been hospitalized for the last 6 months for acute exacerbation or symptoms worsening. Patients hospitalized during the last 6 months for social reasons or are currently hospitalized for social reasons can be included only with Sponsor's Responsible Medical Officer's approval, and the social reasons must be documented in the electronic case report form (eCRF).
  • Patient with a score of > 20 on the PANSS negative subscore (the original PANSS scale [ Sum of N1+N2+N3+N4+N5+N6+N7]) at Screening (Visit 1) and Baseline (Visit 3) AND \< 4 points absolute difference between 2 visits.
  • Patients can be on any psychotropic before the trial if the psychotropics can be discontinued at the beginning of the phase without risking the patient's clinical status or safety.
  • No history of violence against self or others during the last 1 year.
  • Female patient who are not of , defined as women who are (defined as spontaneous amenorrhoea for at least 1 year or spontaneous amenorrhoea for at least 6 months confirmed by follicle stimulating hormone result of ≥ 40 IU/mL) or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy).
  • Female patient, if of childbearing potential, must test negative for pregnancy and must be using a double barrier method.
  • Patient must be extensive metabolizers for cytochrome P450 (CYP2D6), defined as a subject that has at least one functional allel (e.g., *1 or *2), as determined by study-specific genotyping test before the first drug dose is administered.
  • Patient and the caregiver are considered by the investigator to be reliable and likely to cooperate with the assessment procedures.

Exclusion criteria

Exclusion Criteria:

  • Current major depressive disorder, bipolar disorder, panic disorder, obsessive compulsive disorder, or intellectual disability (intellectual developmental disorder diagnosed by age 14).
  • Patient with PANSS item score of > 4 on: P4 excitement/hyperactivity, P6 suspiciousness/persecution, P7 hostility, G8 uncooperativeness, G14 poor impulse control.
  • A Calgary Depression Scale for Schizophrenia (CDSS) total score > 6.
  • A score of ≥ 2 on any 2 items 1, 2, or 3, or a score of ≥ 3 on item 4 of the Barnes Akathisia Rating Scale (BARS).
  • Patient's condition is due to direct psychological effects of a substance (e.g., a drug of abuse, or medication) or a general medical condition.
  • Has a current or recent history of serious suicidal behavior within the past 1 year.
  • Patient has a history of substance use disorder within 3 months of the Screening visit (excluding caffeine and cigarette smoking).
  • Positive urine drug screen for drugs of abuse (cocaine, methadone, amphetamines, cannabinoids, opiates, benzodiazepines, and barbiturates), tricyclic antidepressants (TCA), and alcohol (except for prescription benzodiazepines).
  • Patient who cannot be discontinued from psychotropics other than those allowed.
  • Patient who received clozapine within 6 months of the Screening visit.
  • Patient receiving treatment with long-acting or depot antipsychotic medication unless his/her next scheduled dose will occur during the protocol Screening period and can be omitted to allow for sufficient before receiving the study drug.
  • Patient with a history of significant other major or unstable neurological, neurosurgical (e.g., head trauma), metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, or urological disorder.
  • Patient with a history of seizures (patient with a history of a single childhood febrile seizure may be enrolled in this study).
  • Patient who has had electroconvulsive therapy (ECT), vagal nerve stimulation (VNS), or repetitive trans-cranial magnetic stimulation (r-TMS) within the 6 months prior to the Screening visit or who are scheduled for ECT, VNS, or r-TMS at any time during the study.
  • Patient with abnormalities in hematology, blood chemistry, , or physical examination not resolved by the Baseline visit which according to Investigator can interfere with study participation.
  • Current systemic infection (e.g., , , [HIV], tuberculosis). Patients with positive Hepatitis B core antibody test and negative Hepatitis B surface Antigen (HBsAg) may be included in the study if aminotransferase levels ( (ALT)/ serum glutamic pyruvic transaminase (SGPT) [ALT/SGPT] and aspartate aminotransferase (AST)/ serum glutamic oxaloacetic transaminase (SGOT) [AST/SGOT] do not exceed 2 times (ULN).
  • Patient who requires or may require concomitant treatment with any other medication likely to increase (e.g., paroxetine, fluoxetine, duloxetine, amiodarone).
  • Patient who requires medication inhibiting CYP 2D6 or CYP 3A4.
  • Patient with a clinically significant ECG abnormality that could be a safety issue in the study, including QT interval value corrected for heart rate using the Fridericia's formula (QTcF) > 430 msec for males and > 450 msec for females.
  • Patient with a history of myocardial infarction based on medical history or ECG findings at Screening.
  • Familial or personal history of long QT syndrome or with additional risk factors for Torsade de Pointes.
  • Subjects whose safety laboratory results show hypokalemia, hypomagnesemia, hypocalcemia.
  • Patients with unexplained syncope.
  • Woman of , or man, who are unwilling or unable to use accepted methods of .
  • Woman with a positive pregnancy test, is lactating, or is planning to become pregnant during the study.
  • Patient who participated in another clinical study within 3 months prior to Screening, or received roluperidone previously, or has previously participated in > 2 clinical studies with experimental medication (previous participation in 3 clinical studies with experimental medication will require approval of the sponsor before eligibility is determined).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
515 participants (actual)

Study arms

  • Experimental
    Roluperidone 64 mg

    Roluperidone 64 mg for entire study

    Drug: Roluperidone 64 mg

  • Experimental
    Roluperidone 32 mg

    Roluperidone mg for entire study

    Drug: Roluperidone 32 mg

  • Placebo comparator
    Placebo-1

    Placebo for 12 weeks followed by Roluperidone 64 mg during open-label extension

    Drug: Placebo Oral Tablet · Drug: Roluperidone 64 mg

  • Placebo comparator
    Placebo-2

    Placebo for 12 weeks followed by Roluperidone 32 mg during open-label extension

    Drug: Placebo Oral Tablet · Drug: Roluperidone 32 mg

Interventions

  • DrugPlacebo Oral Tablet

    Placebo administered as a single dose once daily

  • Roluperidone administered as a single dose once daily

  • Roluperidone administered as a single dose once daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS)

    The Marder negative symptoms factor score (NSFS) derived from the complete Positive and Negative Syndrome Scale (PANSS) has been the most frequently used scale in schizophrenia clinical studies focusing on negative symptoms The PANSS measures comprehensive psychiatric symptoms, including positive, negative, and general symptoms. The full PANSS rates the patient on 30 different symptoms from 1 (absent) to 7 (extreme) based on an interview as well as reports of family members or primary care hospital workers. The NSFS consists of the sum of the negative symptom PANSS items N1, N2, N3, N4, N6, G7, and G16 (minimum score = 7; maximum score = 49). Higher scores indicate more severe symptoms.

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

Secondary outcomes

  1. Change From Baseline to Week 12 in Personal and Social Performance (PSP)

    The PSP scale is a validated clinician-rated scale that measures personal and social functioning in 4 domains: socially useful activities (eg, work and study), personal and social relationships, self care, and disturbing and aggressive behaviors. It is a reliable, quick measure of personal and social functioning of patients with schizophrenia and can be used on patients in the acute and stable stage. PSP is a 100-point scale, divided into 10 equal intervals. The score is based on the assessment of a patient's performance in the 4 domains. Lower scores of 1 to 30 reflected poor functioning that the patient required intensive support or supervision; scores of 31 to 60 reflected varying degrees of disability; and scores of 71 to 100 reflected absence of disability or only mild difficulties.

    Time frame: Baseline, Week 4, Week 8, and Week 12

  2. Change From Baseline to Week 12 in Clinical Global Impression of Severity (CGI-S)

    The Clinical Global Impression of Severity (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients

    Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

  3. Number of Participants With Potentially Clinically Significant Laboratory Values (Whole Study Period; Safety Population)

    Laboratory abnormalities were determined using pre-defined normal ranges. Clinical laboratory values were considered potentially clinically significant (PCS) for select parameters of hematology, chemistry, and urinalysis. The number and percentage of patients experiencing PCS laboratory abnormalities post-baseline were summarized by treatment group.

    Time frame: Entire study (which includes double-blind and open-label periods) from Baseline to Week 54 (referred to as the "whole study period")

  4. Number of Participants With Potentially Clinically Significant ECG Parameters (Whole Study Period; Safety Population)

    QTcF values were tabulated for their absolute values and tabulated relative to Baseline measurements in order to detect individual QTcF changes. The number and percentage of patients who met criteria for potentially clinically significant (PCS) values were summarized.

    Time frame: Entire study (which includes double-blind and open-label periods) from Baseline to Week 54 (referred to as the "whole study period")

  5. Number of Participants With Potentially Clinically Significant Vital Signs (Whole Study Period; Safety Population)

    The number and percentage of patients with any potentially clinically significant (PCS) vital sign (systolic blood pressure, diastolic blood pressure, heart rate/pulse rate, temperature) occurring post-Baseline were summarized.

    Time frame: Entire study (which includes double-blind and open-label periods) from Baseline to Week 54 (referred to as the "whole study period")

  6. Safety Assessment - Abnormal Involuntary Movement Scale (AIMS)

    AIMS is rating scale that was designed to measure tardive dyskinesia (TD). For the scoring, the AIMS scale has 14 items. The first 10 items (under categories of Facial and Oral Movements, Extremity Movements, Trunk Movements, and Global Judgements) are rated from 0 (none) to 4 (severe); the remaining 4 items (Dental Status) are rated "yes" and "no" and not counted. The analysis is limited to items 1 to 10, with each rated from 0 to 4. The total score is the sum of all 10 items and with values ranging from 0 to 40. For the analysis, the observed composite movement (total) score will be summarized by treatment group and study visit. Higher scores imply worse outcome.

    Time frame: Study Baseline Day -1, Active Baseline last assessment on placebo at Week 12, as appropriate, Weeks 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 54. Active Baseline=last assessment before receiving Roluperidone.

  7. Safety Assessments - Barnes Akathisia Rations Scale (BARS)

    The BARS is a multiple-choice questionnaire that clinicians used to provide an assessment of akathisia. The BARS scale has 3 items that are rated from 0 (absence/no distress) to 3 (most severe). The BARS rating scale is scored by summing the scales for Objective Akathisia, Subjective Awareness of Restlessness and Subjective Distress Related to Restlessness yielding a total score ranging from 0 to 9. The Total score, which has a possible range from 0-9, is reported. Higher scores imply worse outcome.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, and Week 12

  8. Safety Assessments -Simpson-Angus Scale (S-AS) Score

    The S-AS is an established reliable and valid rating scale that measures drug-induced extrapyramidal syndromes using 10 items rated from 0 = not present to 4 = extremely severe. It consisted of 1 item measuring gait (hypokinesia), 6 items measuring rigidity (arm dropping, shoulder shacking, elbow rigidity, wrist rigidity, leg pendulousness, and head dropping) and 3 items measuring glabella tap, tremor, and salivation. As such, the range of scores was 0 to 40, with increased scores indicating increased severity.

    Time frame: Study Baseline Day -1, Active Baseline last assessment on placebo at Week 12, as appropriate, Weeks 13, 14, 15, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 54. Active Baseline=last assessment before receiving Roluperidone.

  9. Safety Assessments - Sheehan Suicidality Tracking Scale (STS) Total Score

    Sheehan Suicidality Tracking Scale (STS) is a prospective rating scale that tracks treatment-emergent suicidal ideation and behaviors. Scoring: Each item is scored on a 5-point Likert scale from 0 (not at all) to 4 (extremely). Data from the STS can be analyzed as individual item scores, a subscore for suicidal ideation (sum of scores from items 2, 3, and 4, plus score from item 5 if ≤ 1), a subscore for suicidal behavior (sum of scores from items 6, 7, and 8, plus score from item 5 if \> 1) and the total scale score (calculated by add scores from Questions 1a (only if 1b is coded YES), + 2 through 11 + \[the highest of 12 or any row of 16\] + \[the highest of 14 or any row of 15\] + 17 + 20. Analysis: The total scale score will be summarized by treatment group and study visit. Complete data will be presented in patient data listings by treatment group and visit. The total score is the sum of all 16 questions and with values ranging from 0 to 64. Higher scores imply worse outcome.

    Time frame: Study Baseline Day -1, Active Baseline last assessment on placebo at Week 12, as appropriate, Weeks 13, 14, 15, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 54. Active Baseline=last assessment before receiving Roluperidone.

07

Results

Posted Apr 28, 2023

Participant flow

Double Blind
Participant flow — Double Blind
MilestonePlacebo in Double Blind to Roluperidone 32 mg in Open LabelPlacebo in Double Blind to Roluperidone 64 mg in Open LabelRoluperidone 32 mg at Any TimeRoluperidone 64 mg at Any TimePlacebo in Double Blind
Started00170171172
Completed00107104122
Not completed00636750
Open-Label Extension
Participant flow — Open-Label Extension
MilestonePlacebo in Double Blind to Roluperidone 32 mg in Open LabelPlacebo in Double Blind to Roluperidone 64 mg in Open LabelRoluperidone 32 mg at Any TimeRoluperidone 64 mg at Any TimePlacebo in Double Blind
Started59631071040
Completed353672590
Not completed242735450
Whole Study
Participant flow — Whole Study
MilestonePlacebo in Double Blind to Roluperidone 32 mg in Open LabelPlacebo in Double Blind to Roluperidone 64 mg in Open LabelRoluperidone 32 mg at Any TimeRoluperidone 64 mg at Any TimePlacebo in Double Blind
Started0022923450
Completed00107950
Not completed0012213950

Outcome measures

PrimaryChange From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS)

The Marder negative symptoms factor score (NSFS) derived from the complete Positive and Negative Syndrome Scale (PANSS) has been the most frequently used scale in schizophrenia clinical studies focusing on negative symptoms The PANSS measures comprehensive psychiatric symptoms, including positive, negative, and general symptoms. The full PANSS rates the patient on 30 different symptoms from 1 (absent) to 7 (extreme) based on an interview as well as reports of family members or primary care hospital workers. The NSFS consists of the sum of the negative symptom PANSS items N1, N2, N3, N4, N6, G7, and G16 (minimum score = 7; maximum score = 49). Higher scores indicate more severe symptoms.

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Mean · score on a scale
Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS)
score on a scaleRoluperidone 32 mgRoluperidone 64 mgPlacebo
Baseline25.2 ± 3.4325.3 ± 3.2624.3 ± 3.01
Change from Baseline to Week 2-1.2 ± 2.22-1.7 ± 2.47-1.2 ± 2.46
Change from Baseline to Week 4-2.6 ± 2.57-2.8 ± 2.92-1.8 ± 2.99
Change from Baseline to Week 8-3.4 ± 3.49-3.8 ± 3.32-2.8 ± 3.44
Change from Baseline to Week 12-3.7 ± 3.20-4.5 ± 3.85-3.5 ± 3.97
Statistical analysis
  • Roluperidone 64 mg vs Placebo · Mixed Models Analysis · p = 0.043 (The p-values must be ≤0.025 to allow for rejecting the null hypothesis for the representative dose.)The Kenward-Roger approximation will be used to estimate denominator degrees of freedom.
SecondaryChange From Baseline to Week 12 in Personal and Social Performance (PSP)

The PSP scale is a validated clinician-rated scale that measures personal and social functioning in 4 domains: socially useful activities (eg, work and study), personal and social relationships, self care, and disturbing and aggressive behaviors. It is a reliable, quick measure of personal and social functioning of patients with schizophrenia and can be used on patients in the acute and stable stage. PSP is a 100-point scale, divided into 10 equal intervals. The score is based on the assessment of a patient's performance in the 4 domains. Lower scores of 1 to 30 reflected poor functioning that the patient required intensive support or supervision; scores of 31 to 60 reflected varying degrees of disability; and scores of 71 to 100 reflected absence of disability or only mild difficulties.

Time frame:
Baseline, Week 4, Week 8, and Week 12
Reported as:
Mean · score on a scale
Change From Baseline to Week 12 in Personal and Social Performance (PSP)
score on a scaleRoluperidone 32 mgRoluperidone 64 mgPlacebo
Baseline52.7 ± 12.2853.0 ± 10.6052.9 ± 11.02
Change from Baseline to Week 41.6 ± 6.103.2 ± 6.301.2 ± 5.92
Change from Baseline to Week 83.6 ± 7.095.0 ± 6.763.1 ± 7.82
hange from Baseline to Week 124.6 ± 7.986.2 ± 8.674.2 ± 7.48
Statistical analysis
  • Roluperidone 64 mg vs Placebo · Mixed Models Analysis · p = 0.016 (The p-values must be ≤0.025 to allow for rejecting the null hypothesis for the representative dose.)The Kenward-Roger approximation will be used to estimate denominator degrees of freedom.
SecondaryChange From Baseline to Week 12 in Clinical Global Impression of Severity (CGI-S)

The Clinical Global Impression of Severity (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients

Time frame:
Baseline, Week 2, Week 4, Week 8, and Week 12
Reported as:
Mean · score on a scale
Change From Baseline to Week 12 in Clinical Global Impression of Severity (CGI-S)
score on a scaleRoluperidone 32 mgRoluperidone 64 mgPlacebo
Baseline4.0 ± 0.624.0 ± 0.614.0 ± 0.58
Change from Baseline to Week 2-0.1 ± 0.44-0.1 ± 0.54-0.1 ± 0.50
Change from Baseline to Week 4-0.2 ± 0.49-0.3 ± 0.55-0.1 ± 0.44
Change from Baseline to Week 8-0.3 ± 0.61-0.4 ± 0.68-0.2 ± 0.60
Change from Baseline to Week 12-0.4 ± 0.68-0.4 ± 0.67-0.3 ± 0.63
SecondaryNumber of Participants With Potentially Clinically Significant Laboratory Values (Whole Study Period; Safety Population)

Laboratory abnormalities were determined using pre-defined normal ranges. Clinical laboratory values were considered potentially clinically significant (PCS) for select parameters of hematology, chemistry, and urinalysis. The number and percentage of patients experiencing PCS laboratory abnormalities post-baseline were summarized by treatment group.

Time frame:
Entire study (which includes double-blind and open-label periods) from Baseline to Week 54 (referred to as the "whole study period")
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Values (Whole Study Period; Safety Population)
ParticipantsRoluperidone 32 mgRoluperidone 64 mgPlacebo
Low potentially clinically significant laboratory values433718
High potentially clinically significant laboratory values514821
SecondaryNumber of Participants With Potentially Clinically Significant ECG Parameters (Whole Study Period; Safety Population)

QTcF values were tabulated for their absolute values and tabulated relative to Baseline measurements in order to detect individual QTcF changes. The number and percentage of patients who met criteria for potentially clinically significant (PCS) values were summarized.

Time frame:
Entire study (which includes double-blind and open-label periods) from Baseline to Week 54 (referred to as the "whole study period")
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant ECG Parameters (Whole Study Period; Safety Population)
ParticipantsRoluperidone 32 mgRoluperidone 64 mgPlacebo
Highest absolute QTcF interval > 450 -480 msec10241
Highest absolute QTcF interval > 480 -500 msec020
Highest absolute QTcF interval > 500 msec020
SecondaryNumber of Participants With Potentially Clinically Significant Vital Signs (Whole Study Period; Safety Population)

The number and percentage of patients with any potentially clinically significant (PCS) vital sign (systolic blood pressure, diastolic blood pressure, heart rate/pulse rate, temperature) occurring post-Baseline were summarized.

Time frame:
Entire study (which includes double-blind and open-label periods) from Baseline to Week 54 (referred to as the "whole study period")
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Vital Signs (Whole Study Period; Safety Population)
ParticipantsRoluperidone 32 mgRoluperidone 64 mgPlacebo
Number of Participants With Potentially Clinically Significant Vital Signs (Whole Study Period; Safety Population)372820
SecondarySafety Assessment - Abnormal Involuntary Movement Scale (AIMS)

AIMS is rating scale that was designed to measure tardive dyskinesia (TD). For the scoring, the AIMS scale has 14 items. The first 10 items (under categories of Facial and Oral Movements, Extremity Movements, Trunk Movements, and Global Judgements) are rated from 0 (none) to 4 (severe); the remaining 4 items (Dental Status) are rated "yes" and "no" and not counted. The analysis is limited to items 1 to 10, with each rated from 0 to 4. The total score is the sum of all 10 items and with values ranging from 0 to 40. For the analysis, the observed composite movement (total) score will be summarized by treatment group and study visit. Higher scores imply worse outcome.

Time frame:
Study Baseline Day -1, Active Baseline last assessment on placebo at Week 12, as appropriate, Weeks 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 54. Active Baseline=last assessment before receiving Roluperidone.
Reported as:
Mean · score on a scale
Safety Assessment - Abnormal Involuntary Movement Scale (AIMS)
score on a scalePlacebo in DB to Roluperidone 32 mg in OL ExtensionPlacebo in DB to Roluperidone 64 mg in OL ExtensionRoluperidone 32 mg at Any TimeRoluperidone 64 mg at Any Time
Study Baseline0.2 ± 1.230.1 ± 0.620.4 ± 1.400.3 ± 1.04
Active Baseline0.2 ± 1.450.1 ± 0.520.4 ± 1.200.3 ± 1.15
Week 160.2 ± 0.880.1 ± 0.560.5 ± 1.380.2 ± 1.18
Week 200.1 ± 0.500.1 ± 0.560.4 ± 1.600.2 ± 1.06
Week 240.1 ± 0.510.1 ± 0.570.4 ± 1.310.2 ± 1.37
Week 280.1 ± 0.520.1 ± 0.590.4 ± 1.300.2 ± 1.38
Week 320.1 ± 0.550.1 ± 0.600.4 ± 1.190.2 ± 1.45
Week 360.1 ± 0.690.1 ± 0.630.4 ± 1.290.2 ± 1.48
Week 400.1 ± 0.560.1 ± 0.630.3 ± 1.060.3 ± 1.53
Week 440.1 ± 0.330.0 ± 0.160.3 ± 1.170.1 ± 0.40
Week 480.1 ± 0.360.2 ± 0.590.4 ± 1.380.3 ± 1.57
Week 520.1 ± 0.330.0 ± 0.170.3 ± 1.310.3 ± 1.63
Week 540.1 ± 0.340.0 ± 0.170.5 ± 1.550.3 ± 1.63
SecondarySafety Assessments - Barnes Akathisia Rations Scale (BARS)

The BARS is a multiple-choice questionnaire that clinicians used to provide an assessment of akathisia. The BARS scale has 3 items that are rated from 0 (absence/no distress) to 3 (most severe). The BARS rating scale is scored by summing the scales for Objective Akathisia, Subjective Awareness of Restlessness and Subjective Distress Related to Restlessness yielding a total score ranging from 0 to 9. The Total score, which has a possible range from 0-9, is reported. Higher scores imply worse outcome.

Time frame:
Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, and Week 12
Reported as:
Mean · score on a scale
Safety Assessments - Barnes Akathisia Rations Scale (BARS)
score on a scaleRoluperidone 32 mgRoluperidone 64 mgPlacebo
Baseline0.1 ± 0.390.1 ± 0.420.1 ± 0.39
Week 10.1 ± 0.490.1 ± 0.390.1 ± 0.34
Week 20.2 ± 0.550.1 ± 0.470.1 ± 0.41
Week 30.1 ± 0.520.1 ± 0.430.1 ± 0.32
Week 40.1 ± 0.410.1 ± 0.410.1 ± 0.32
Week 80.1 ± 0.400.1 ± 0.440.0 ± 0.27
Week 120.1 ± 0.460.1 ± 0.370.0 ± 0.22
SecondarySafety Assessments -Simpson-Angus Scale (S-AS) Score

The S-AS is an established reliable and valid rating scale that measures drug-induced extrapyramidal syndromes using 10 items rated from 0 = not present to 4 = extremely severe. It consisted of 1 item measuring gait (hypokinesia), 6 items measuring rigidity (arm dropping, shoulder shacking, elbow rigidity, wrist rigidity, leg pendulousness, and head dropping) and 3 items measuring glabella tap, tremor, and salivation. As such, the range of scores was 0 to 40, with increased scores indicating increased severity.

Time frame:
Study Baseline Day -1, Active Baseline last assessment on placebo at Week 12, as appropriate, Weeks 13, 14, 15, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 54. Active Baseline=last assessment before receiving Roluperidone.
Reported as:
Mean · score on a scale
Safety Assessments -Simpson-Angus Scale (S-AS) Score
score on a scalePlacebo in DB to Roluperidone 32 mg in OL ExtensionPlacebo in DB to Roluperidone 64 mg in OL ExtensionRoluperidone 32 mg at Any TimeRoluperidone 64 mg at Any Time
Study Baseline0.4 ± 0.800.5 ± 1.250.8 ± 2.180.6 ± 1.53
Active Baseline0.3 ± 0.830.1 ± 0.480.8 ± 2.100.5 ± 1.44
Week 130.2 ± 0.630.2 ± 0.600.8 ± 1.840.3 ± 1.04
Week 140.3 ± 0.810.2 ± 0.640.7 ± 1.770.4 ± 1.56
Week 150.2 ± 0.480.2 ± 0.640.7 ± 1.740.5 ± 1.61
Week 160.1 ± 0.340.1 ± 0.520.7 ± 1.680.5 ± 1.63
Week 200.1 ± 0.330.1 ± 0.520.6 ± 1.650.5 ± 1.64
Week 240.1 ± 0.400.1 ± 0.520.6 ± 1.560.5 ± 1.73
Week 280.2 ± 0.480.1 ± 0.530.7 ± 1.650.3 ± 1.66
Week 320.2 ± 0.490.1 ± 0.540.6 ± 1.600.4 ± 1.68
Week 360.2 ± 0.500.1 ± 0.540.6 ± 1.650.4 ± 1.70
Week 400.1 ± 0.300.1 ± 0.570.6 ± 1.360.4 ± 1.69
Week 440.3 ± 0.770.1 ± 0.350.6 ± 1.560.3 ± 0.82
Week 480.4 ± 1.520.1 ± 0.320.7 ± 1.690.5 ± 1.79
Week 520.1 ± 0.350.1 ± 0.340.5 ± 1.420.5 ± 1.84
Week 540.2 ± 0.490.2 ± 0.760.7 ± 1.750.5 ± 1.83
SecondarySafety Assessments - Sheehan Suicidality Tracking Scale (STS) Total Score

Sheehan Suicidality Tracking Scale (STS) is a prospective rating scale that tracks treatment-emergent suicidal ideation and behaviors. Scoring: Each item is scored on a 5-point Likert scale from 0 (not at all) to 4 (extremely). Data from the STS can be analyzed as individual item scores, a subscore for suicidal ideation (sum of scores from items 2, 3, and 4, plus score from item 5 if ≤ 1), a subscore for suicidal behavior (sum of scores from items 6, 7, and 8, plus score from item 5 if \> 1) and the total scale score (calculated by add scores from Questions 1a (only if 1b is coded YES), + 2 through 11 + \[the highest of 12 or any row of 16\] + \[the highest of 14 or any row of 15\] + 17 + 20. Analysis: The total scale score will be summarized by treatment group and study visit. Complete data will be presented in patient data listings by treatment group and visit. The total score is the sum of all 16 questions and with values ranging from 0 to 64. Higher scores imply worse outcome.

Time frame:
Study Baseline Day -1, Active Baseline last assessment on placebo at Week 12, as appropriate, Weeks 13, 14, 15, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 54. Active Baseline=last assessment before receiving Roluperidone.
Reported as:
Mean · score on a scale
Safety Assessments - Sheehan Suicidality Tracking Scale (STS) Total Score
score on a scalePlacebo in DB to Roluperidone 32 mg in OL ExtensionPlacebo in DB to Roluperidone 64 mg in OL ExtensionRoluperidone 32 mg at Any TimeRoluperidone 64 mg at Any Time
Study Baseline0.0 ± 0.000.0 ± 0.150.0 ± 0.460.0 ± 0.08
Active Baseline0.0 ± 0.130.0 ± 0.000.0 ± 0.000.0 ± 0.10
Week 12.10.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
Week 12.20.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
Week 130.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.10
Week 140.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
Week 150.0 ± 0.140.0 ± 0.00.0 ± 0.00.0 ± 0.0
Week 160.0 ± 0.00.0 ± 0.00.0 ± 0.100.0 ± 0.0
Week 200.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.41
Week 240.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
Week 280.2 ± 1.440.0 ± 0.00.0 ± 0.110.0 ± 0.0
Week 320.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
Week 360.0 ± 0.00.0 ± 0.00.0 ± 0.110.0 ± 0.0
Week 400.0 ± 0.00.0 ± 0.00.0 ± 0.110.0 ± 0.0
Week 440.0 ± 0.00.0 ± 0.00.0 ± 0.220.0 ± 0.0
Week 480.1 ± 0.490.0 ± 0.00.0 ± 0.120.0 ± 0.38
Week 520.0 ± 0.170.0 ± 0.00.0 ± 0.00.0 ± 0.0
Week 540.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0

Adverse events

Collected over Entire study (which includes double-blind and open-label periods) from Baseline to Week 54 (referred to as the "whole study period").. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo in Double Blind to Roluperidone 32 mg in Open Label0/59 (0%)1/59 (1.7%)2/59 (3.4%)
Placebo in Double Blind to Roluperidone 64 mg in Open Label1/63 (1.6%)5/63 (7.9%)7/63 (11.1%)
Roluperidone 32 mg at Any Time2/229 (0.9%)18/229 (7.9%)30/229 (13.1%)
Roluperidone 64 mg at Any Time1/234 (0.4%)21/234 (9%)39/234 (16.7%)
Placebo0/172 (0%)5/172 (2.9%)22/172 (12.8%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPlacebo in Double Blind to Roluperidone 32 mg in Open LabelPlacebo in Double Blind to Roluperidone 64 mg in Open LabelRoluperidone 32 mg at Any TimeRoluperidone 64 mg at Any TimePlacebo
SchizophreniaPsychiatric disorders1/590/639/2299/2341/172
Psychotic symptomPsychiatric disorders0/590/631/2291/2343/172
AnxietyPsychiatric disorders0/591/631/2292/2340/172
AggressionPsychiatric disorders0/591/631/2291/2340/172
Sleep DisorderPsychiatric disorders0/591/631/2291/2341/172
Hallucination, auditoryPsychiatric disorders0/591/630/2291/2340/172
Pneumonia bacterialInfections and infestations0/591/630/2291/2340/172
Pneumonia viralInfections and infestations0/591/630/2291/2340/172
Femur fractureInjury, poisoning and procedural complications0/591/630/2292/2340/172
ConcussionInjury, poisoning and procedural complications0/591/630/2291/2340/172
Most frequent other events
Most frequent other events
EventPlacebo in Double Blind to Roluperidone 32 mg in Open LabelPlacebo in Double Blind to Roluperidone 64 mg in Open LabelRoluperidone 32 mg at Any TimeRoluperidone 64 mg at Any TimePlacebo
HeadacheNervous system disorders1/595/638/22915/2344/172
InsomniaPsychiatric disorders1/590/637/2294/2347/172
SchizophreniaPsychiatric disorders0/590/636/2295/2345/172
AstheniaGeneral disorders0/591/633/2296/2344/172
Electrocardiogram QT prolongedInvestigations0/591/632/2295/2340/172
AgitationPsychiatric disorders0/590/634/2294/2342/172

Baseline characteristics

Patients who Started Treatment.

Age, Continuous
Age, Continuous(years)Roluperidone 64 mgRoluperidone 32 mgPlaceboTotal
Mean41 ± 9.341 ± 9.441 ± 8.741 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Roluperidone 64 mgRoluperidone 32 mgPlaceboTotal
Female686466198
Male103106106315
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Roluperidone 64 mgRoluperidone 32 mgPlaceboTotal
Hispanic or Latino45312
Not Hispanic or Latino167165169501
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Roluperidone 64 mgRoluperidone 32 mgPlaceboTotal
American Indian or Alaska Native0101
Asian1102
Native Hawaiian or Other Pacific Islander1203
Black or African American18192057
White151147152450
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Roluperidone 64 mgRoluperidone 32 mgPlaceboTotal
United States27272781
Bulgaria363740113
Georgia55212
Israel0426
Moldova68519
Poland65819
Romania19181350
Ukraine726675213
08

Study locations

39 sites
  • Woodland Research Northwest
    Rogers, Arkansas 72758, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Collaborative Neuroscience Network, LLC.
    Garden Grove, California 92845, United States
  • Synergy Clinical Center
    National City, California 91950, United States
  • Collaborative Neuroscience Network, LLC.
    Torrance, California 90502, United States
  • Behavioral Clinical Research, Inc
    North Miami, Florida 33161, United States
  • Research Centers of America, LLC
    Oakland Park, Florida 33334, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Uptown Research Institute LLC
    Chicago, Illinois 60640, United States
  • Hassman Research Institute, LLC.
    Berlin, New Jersey 08009, United States
  • The Nathan Kline Institute for Psychiatric Research
    Orangeburg, New York 10962, United States
  • InSite Clinical Research LLC
    DeSoto, Texas 75115, United States
  • Pillar Clinical Research LLC
    Richardson, Texas 75080, United States
  • "State Psychiatric Hospital - Tserova Koria"; Department for Active Treatment of Severe Psychosis - male; Department for Active Treatment of Severe Psychosis - male
    Tserova Koria, Veliko Tarnovo District, Bulgaria
  • "Mental Health Center Prof. Dr. Ivan Temkov - Burgas" EOOD Department For Treatment of Emergency Psychiatry Conditions
    Burgas, Bulgaria
  • State Psychiatry Hospital - Lovech
    Lovech, Bulgaria
  • State Psychiatry Hospital "Sveti Ivan Rilski" Department of General Psychiatry for adults "closed type" - males; Department of General Psychiatry for adults "closed type" - females
    Novi Iskar, Bulgaria
  • 'Mental Health Center Plovdiv"-EOOD Department for treatment of acute female/male psychoses with endogenous, exogenous, organic psychotic disturbances of the personality
    Plovdiv, Bulgaria
  • Multiprofile Hospital for Active Treatment - Targovishte" AD Department of Psychiatry
    Targovishte, Bulgaria
  • "Mental Health Center - Vratsa" General Psychiatric Department
    Vratsa, Bulgaria
  • Samodzielny Publiczny Psychiatryczny zakład opieki zdrowotnej im Dr. Stanisława Deresza w Choroszczy
    Choroszcz, Poland
  • Medical University of Gdańsk, Department of Psychiatry UCK
    Gdansk, Poland
  • Klinika Psychiatryczna Inventiva
    Tuszyn, Poland
  • Communal Institution "Dnipropetrovsk Regional Clinical Hospital n.a. I.I. Mechnikov," Regional Centre for Psychosomatic Disorders based on Psychoneurological Department
    Dnipro, Ukraine
  • Ivano-Frankivsk National Medical University (IFNMU) - Regional Psycho-Neurological Hospital #3
    Ivano-Frankivsk, Ukraine
  • Kharkiv Railway Clinical Hospital N°1 of Branche "Health Center" of the Public joint stock company "Ukrainian Railway," Psychiatry Department
    Kharkiv, Ukraine
  • State Institution "Institute of Neurology, Psychiatry and Narcology of National Academy of Medical Science of Ukraine," Department of Emergency Psychiatry and Narcology
    Kharkiv, Ukraine
  • State Institution "Institute of Neurology, Psychiatry and Narcology of National Academy of Medical Science of Ukraine," Department of Neuroses and Borderline Conditions
    Kharkiv, Ukraine
  • State Institution "Institute of Neurology, Psychiatry and Narcology of National Academy of Medical Sciences of Ukraine," Department of Clinical, Social and Child Psychiatry
    Kharkiv, Ukraine
  • Kyiv Regional Medical Incorporation "Psychiatry," Centre of Novel Treatment and Rehabilitation of Psychotic Disorders based on Department #29 and Department #30
    Kyiv, Ukraine
  • Communal Institution of Lviv Regional Council "Lviv Regional Clinical Psychiatric Hospital," Department #20
    Lviv, Ukraine
  • Communal Institution of Lviv Regional Council "Lviv Regional Clinical Psychiatry Hospital," General Psychiatric Mixed Department #25
    Lviv, Ukraine
  • Odessa Regional Medical Centre of Mental Health, Dept. #6 (male), Dept. #12 (female)
    Odessa, Ukraine
  • Kyiv Regional Medical Incorporation "Psychiatry," Centre of Novel Treatment and Rehabilitation of Psychotic Disorders based on Department #29 and Department #30
    Oleksandrivka, Ukraine
  • "Ukrainian medical stomatological academy," Chair of psychiatry, narcology and medical psychology based on Poltava Regional Clinical Psychiatric Hospital named after O.F. Maltsev, female acute general psych. dept. 5-b, male acute general psych. dept 2-a
    Poltava, Ukraine
  • Communal Institution "Cherkasy Regional Psychiatric Hospital"
    Smila, Ukraine
  • Municipal Institution Kherson Regional Psychiatric Hospital of Regional Council
    Stepanovka, Ukraine
  • Ternopil Regional Municipal Clinical Psychoneurological Hospital
    Ternopil, Ukraine
  • Municipal Institution "Vinnytsya Regional Psychoneurological Hospital n.a. Acad. O.I. Yushchenko," Male Department No 14, Female Department No 15
    Vinnytsia, Ukraine
09

References and documents

Publications

  • Davidson M, Saoud J, Staner C, Noel N, Werner S, Luthringer E, Walling D, Weiser M, Harvey PD, Strauss GP, Luthringer R. Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia. Schizophr Bull. 2022 May 7;48(3):609-619. doi: 10.1093/schbul/sbac013. PubMed 35211743 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in May 2020, 29 months.

Results were first posted in Apr 2023, 2 years 11 months after primary completion. A results delay was requested in Jan 2021.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 29 months is close to that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2017
First posted
Jan 11, 2018
StartActual
Dec 15, 2017
Primary completionActual
May 26, 2020
CompletionActual
Feb 15, 2021
Results delay requested
Jan 5, 2021
Results first posted
Apr 28, 2023
Last update
Apr 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03397134
Lead sponsor
Minerva Neurosciences
Responsible party
Sponsor
First posted
Jan 11, 2018
Start date
Dec 15, 2017
Primary completion
May 26, 2020
Completion
Feb 15, 2021
Results posted
Apr 28, 2023
Last update
Apr 28, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roluperidone

Start the discussion